{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:48:19Z","timestamp":1782488899194,"version":"3.54.5"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.canlet.2019.04.018","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T12:04:06Z","timestamp":1556625846000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Management of immune related adverse events induced by immune checkpoint inhibition"],"prefix":"10.1016","volume":"456","author":[{"given":"Andreas","family":"Teufel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzuo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"H\u00e4rtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bornschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.04.018_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-016-0130-5","article-title":"A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet","volume":"6","author":"D'Errico","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.21037\/jgo.2017.05.01","article-title":"Immunotherapy in gastrointestinal cancers","volume":"8","author":"Grierson","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-017-0454-7","article-title":"Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress","volume":"10","author":"Myint","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clinthera.2018.01.005","article-title":"An overview of immune checkpoint inhibitors in gynecologic cancers","volume":"40","author":"Castellano","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.canlet.2019.04.018_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bju.13518","article-title":"Recent advances in immuno-oncology and its application to urological cancers","volume":"118","author":"Mataraza","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2019.04.018_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.21037\/jgo.2016.08.06","article-title":"The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1","volume":"7","author":"Jin","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/PAS.0000000000000949","article-title":"The relationship between mismatch repair deficiency and PD-L1 expression in breast carcinoma","volume":"42","author":"Mills","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2019.04.018_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2019.04.018_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40880-018-0274-3","article-title":"Precision medicine becomes reality-tumor type-agnostic therapy","volume":"38","author":"Yan","year":"2018","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2019.04.018_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2018.10.045","article-title":"Immunotherapy in pancreatic cancer: new hope or mission impossible?","volume":"445","author":"Jiang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.04.018_bib11","unstructured":"https:\/\/investors.merck.com\/news\/press-release-details\/2019\/Merck-Provides-Update-on-KEYNOTE-240-a-Phase-3-Study-of-KEYTRUDA-pembrolizumab-in-Previously-Treated-Patients-with-Advanced-Hepatocellular-Carcinoma\/default.aspx."},{"key":"10.1016\/j.canlet.2019.04.018_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/lio2.235","article-title":"The evolving role of immuno-oncology for the treatment of head and neck cancer","volume":"4","author":"Strome","year":"2019","journal-title":"Laryngoscope Investig. Otolaryngol."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2019.04.018_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000451016","article-title":"Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials","volume":"92","author":"Kudo","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2019.04.018_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4074","article-title":"Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)","volume":"36","author":"Stein","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2019.04.018_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2019.04.018_bib17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2019.04.018_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2019.04.018_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.gene.6363655","article-title":"CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity?","volume":"1","author":"Kristiansen","year":"2000","journal-title":"Genes Immun."},{"key":"10.1016\/j.canlet.2019.04.018_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","article-title":"CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance","volume":"12","author":"Romo-Tena","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.canlet.2019.04.018_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: a growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2019.04.018_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance","volume":"1217","author":"Fife","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2019.04.018_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib26","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.018_bib27","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib28","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2019.04.018_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib31","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2019.04.018_bib32","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.canlet.2019.04.018_bib33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2019.04.018_bib34","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.04.018_bib35","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib37","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.04.018_bib38","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.canlet.2019.04.018_bib40","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.018_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.canlet.2019.04.018_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2019.04.018_bib43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib44","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1574886313666180730114309","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview","volume":"14","author":"Plachouri","year":"2019","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.canlet.2019.04.018_bib47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.04.018_bib50","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Sci. Tech. Rep."},{"key":"10.1016\/j.canlet.2019.04.018_bib51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib52","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.cgh.2016.09.017","article-title":"Nivolumab-induced colitis treated by infliximab","volume":"15","author":"Yanai","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2019.04.018_bib53","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12876-018-0864-1","article-title":"The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review","volume":"18","author":"Yamauchi","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.canlet.2019.04.018_bib55","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2019.04.018_bib56","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib57","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.critrevonc.2018.09.019","article-title":"Liver toxicity in the era of immune checkpoint inhibitors: a practical approach","volume":"132","author":"Belli","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2019.04.018_bib59","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2019.04.018_bib60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2019.04.018_bib61","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.canlet.2019.04.018_bib62","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.04.018_bib63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2019.04.018_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.canlet.2019.04.018_bib65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2019.04.018_bib66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonzalez-Rodriguez","year":"2016","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib67","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/RLU.0b013e3182639765","article-title":"Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab","volume":"38","author":"van der Hiel","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib68","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2019.04.018_bib69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MED.0000000000000357","article-title":"Endocrine dysfunction following immune checkpoint inhibitor therapy","volume":"24","author":"Konda","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.canlet.2019.04.018_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.04.018_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2019.04.018_bib73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.canlet.2019.04.018_bib74","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.canlet.2019.04.018_bib75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Cancer, I. Kidney international network workgroup on immune checkpoint, adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.canlet.2019.04.018_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6627","article-title":"Modeling the cost of immune checkpoint inhibitor-related toxicities","volume":"34","author":"Mason","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib77","series-title":"[Neurological Side Effects of Checkpoint Inhibitors], Nervenarzt","author":"Knauss","year":"2018"},{"key":"10.1016\/j.canlet.2019.04.018_bib78","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.canlet.2019.04.018_bib79","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.canlet.2019.04.018_bib80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.canlet.2019.04.018_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2019.04.018_bib82","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.canlet.2019.04.018_bib83","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.canlet.2019.04.018_bib84","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.canlet.2019.04.018_bib85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2019.04.018_bib86","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","author":"Alabed","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw260","article-title":"Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab","volume":"109","author":"Friedman","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2019.04.018_bib88","doi-asserted-by":"crossref","first-page":"1027323","DOI":"10.1155\/2018\/1027323","article-title":"Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis","volume":"2018","author":"Su","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.canlet.2019.04.018_bib89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2019.04.018_bib90","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.canlet.2019.04.018_bib91","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib92","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.canlet.2019.04.018_bib93","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2019.04.018_bib94","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib95","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4161\/onci.20687","article-title":"Ipilimumab in a Phase II trial of melanoma patients with brain metastases","volume":"1","author":"Margolin","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.04.018_bib96","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib97","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.canlet.2019.04.018_bib98","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.canlet.2019.04.018_bib99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","article-title":"Cardiac complications in immune checkpoint inhibition therapy","volume":"6","author":"Tajiri","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.canlet.2019.04.018_bib100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2019.04.018_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9012","article-title":"Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy","volume":"35","author":"Santini","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519302435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519302435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:43:58Z","timestamp":1759592638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519302435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":101,"alternative-id":["S0304383519302435"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.04.018","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of immune related adverse events induced by immune checkpoint inhibition","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}